Kazia Therapeutics Limited KZIA
7.34 USD +0.34 (+4.86%)
Nov 6, 2026, 9:48 AM EST
7.01 Day range 7.35
4.86 52-week range 17.40
- YTD
- +6.53%
- 1 year
- -2.13%
News
prnewswire.com Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards Recognition Highlights Kazia's Focus on Overcoming Treatment Resistance in Cancer SYDNEY, Nov. 5, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an…
benzinga.com Kazia Therapeutics Says Two Abstracts Highlighting Paxalisib Tumor And Immune Reprogramming Research Accepted For Poster Presentation At 2026 San Antonio Breast Cancer Symposium Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming ActivitySYDNEY, Nov. 2, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an
prnewswire.com Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming Activity SYDNEY, Nov. 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"),…
benzinga.com This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Analysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGCY ($16).- benzinga.com Needham Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $27 Needham analyst Gil Blum initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $27.
benzinga.com This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiate coverage: Buy on AIR Global, Robinhood and Kazia; Outperform on Equinix; Neutral on Zscaler, with price targets.
benzinga.com Guggenheim Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $35 Guggenheim analyst Paul Jeng initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $35.
benzinga.com Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30 Leerink Partners analyst Andrew Berens initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Outperform rating and announces Price Target of $30.- benzinga.com Kazia Therapeutics Announces Sovargen Doses First Participant In Phase 1b/2a Clinical Study Of Paxalisib To Treat Epilepsies Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment…
benzinga.com Kazia Therapeutics Doses First Participant In Its Arm A Of PNOC035 Platform To Evaluate Paxalisib In Combination With Gemcitabine Toi Treat Atypical Teratoid/Rhabdoid Tumor Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor…- benzinga.com BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40 BTIG analyst Kambiz Yazdi maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy and raises the price target from $34 to $40.
benzinga.com Kazia Therapeutics Reports New Preclinical And Translational Data Showing Lead Asset Paxalisib Reduced Tumor Burden By 52% In MSS/pMMR Colorectal Cancer Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further ReductionPaxalisib Was Well…- benzinga.com Kazia Therapeutics Announces New Preclinical Data Showing Safety, Anti-Tumor Activity Of Paxalisib In HR+/HER2- Breast Cancer; First Patient Expected By Year-End 2026 And Full Enrollment By End Of 2027 Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor ActivityThree-Arm Expansion of the Ongoing TNBC Trial Will…
benzinga.com Kazia Therapeutics Prices ~$40M Offering Of 2.58M American Depositary Shares At $17.825 Per ADS Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market session. The market value of their outstanding shares is at $1.6 million. Modular Medical (NASDAQ:MODD)…
benzinga.com Kazia Therapeutics Commences Offering Of American Depositary Shares; Terms Undisclosed Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor…
benzinga.com Canaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29 Canaccord Genuity analyst John Newman initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $29.- benzinga.com Kazia Therapeutics Files Provisional Patent Application Supporting Therapeutic Strategy Designed To Prevent Metastatic Recurrence In Patients With High-Risk Early-Stage Triple-Negative Breast Cancer Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing therapies that reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance,…
- benzinga.com BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34 BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $34.
- benzinga.com Lake Street Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $32 Lake Street initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $32.
- benzinga.com Kazia Therapeutics Appoints James Levine As CFO, Effective June 1 Mr. Levine brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies."James has built an impressive career leading…
benzinga.com Kazia Therapeutics Expands Enrollment In Phase 1b Trial For Breast Cancer Treatment Paxalisib Based on continued encouraging safety, tolerability and clinical activity data observed to date, planned enrollment has increased from 12 to 36 patients.The expansion is intended to further evaluate…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- benzinga.com Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- benzinga.com Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session